Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports - Takeaways - MDSpire

Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports

  • By

  • Jingjing Huang

  • Junlong Cai

  • Wei Cheng

  • Yan Wang

  • June 10, 2026

  • 0 min

Share

  • 1

    Pembrolizumab-induced hypophysitis is a rare immune-related adverse event with unclear long-term outcomes.

  • 2

    The study analyzed 22 patients, median age 66, with symptoms primarily including fatigue and nausea.

  • 3

    Hormone replacement therapy was administered in 81.8% of cases, leading to clinical improvement in 90.9% of patients.

  • 4

    Persistent endocrine dysfunction was noted in 95.5% of patients, with recovery of the hypothalamic-pituitary axis in only one case.

  • 5

    The study emphasizes the need for early recognition and long-term endocrine follow-up for patients with this condition.

Original Source(s)

Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports

  • by Jingjing Huang, Junlong Cai, Wei Cheng, Yan Wang

  • June 10, 2026

Related Content

Immune - cell death index in hepatocellular carcinoma: a multi-omics and machine learning study for prognosis and immunotherapy prediction

A multicenter clinical study on transanal endoscopic sphincter-preserving resection of low rectal tumors

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy